Prosalix Overview
- Year Founded
-
2018
- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Investors
-
2
Prosalix General Information
Description
Developer of a kidney disease medicine designed to treat acid-base imbalances and reduce associated long-term risks. The company offers a user-friendly product with solubility, neutral taste, and easy dosing, enabling patients with kidney diseases to improve their lives and prevent complications.
Contact Information
Website
www.prosalix.comCorporate Office
- Hinterer Schürmattweg 27
- 4203
- Switzerland
Corporate Office
- Hinterer Schürmattweg 27
- 4203
- Switzerland
Prosalix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Later Stage VC | 01-Nov-2023 | Completed | Generating Revenue |
Prosalix Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Oakmont Invest | Venture Capital | Minority | ||
| Spitzhorli Invest | Venture Capital | Minority |
Prosalix FAQs
-
When was Prosalix founded?
Prosalix was founded in 2018.
-
Where is Prosalix headquartered?
Prosalix is headquartered in Switzerland.
-
What industry is Prosalix in?
Prosalix’s primary industry is Drug Discovery.
-
Is Prosalix a private or public company?
Prosalix is a Private company.
-
What is Prosalix’s current revenue?
The current revenue for Prosalix is .
-
Who are Prosalix’s investors?
Oakmont Invest and Spitzhorli Invest have invested in Prosalix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
